Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Key facts

Sponsor

Wright State University

Principal Investigator

David F Fiorentino, MD, PhD

Stanford University

Intervention

Humira(drug)

Eligibility

18 years · All sexes

Timeline

2009 – 2010

Study locations (1)

• Stanford University, Stanford, California, United States

Collaborators

Stanford University · Wake Forest University Health Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →